BPC-157 in Clinical Practice: What the Evidence Actually Supports

Few peptides generate more confident claims. BPC-157 is described as healing tendons, closing ulcers, repairing the gut and accelerating recovery, often by people who are sincere and occasionally by people who are selling it. The underlying research is real, published in indexed journals, and spans three decades.

What follows is an attempt to describe that evidence base accurately: what it contains, what shape it has, and what a clinician can honestly tell a patient who asks.

What the compound is

BPC-157 is a synthetic pentadecapeptide, sequence GEPPPGKPADDAGLV, originally described as a fragment of a larger protein identified in human gastric juice. It was first characterised in the early 1990s by Predrag Sikirić and colleagues at the University of Zagreb, who named the parent molecule Body Protection Compound for its apparent protective effects across multiple tissues.

The proposed mechanisms are plausible and reasonably specific. The compound has been reported to upregulate VEGF receptor 2 signalling and promote angiogenesis, to modulate the nitric oxide system, to influence the FAK-paxillin pathway relevant to fibroblast migration, and to reduce inflammatory cytokine expression. It is unusually stable in gastric juice, which is the basis for claims about oral administration.

None of that is implausible. Angiogenesis and fibroblast migration are exactly what tissue repair requires, and a compound that promotes both would be expected to accelerate healing. The mechanistic story hangs together.

The shape of the literature

This is where careful reading matters, and where most summaries stop too early.

There are well over a hundred peer-reviewed BPC-157 papers, and the findings across them are strikingly consistent: accelerated healing in gastric ulcer models, reduced inflammation in chemically induced colitis, improved tendon and ligament repair, protection against NSAID-induced gastric injury, healing of intestinal anastomoses and fistulas. Taken at face value, that is an impressive body of work.

The complication is its concentration. The large majority of those studies originate from the same research group in Zagreb, and independent replication by unaffiliated laboratories is limited. A 2025 review documented this concentration explicitly. [1] Reporting in STAT in February 2026 examined the same pattern, noting that nearly all the data comes from animal studies and a single group. [2] The lead investigator has also been reported to hold patents on the compound and financial interests in its commercialisation.

This is not an accusation of misconduct, and it should not be read as one. Sikirić's group is a real academic laboratory publishing in indexed journals, and consistent findings from a productive lab are genuine evidence. But independent replication is how the field distinguishes a real effect from a laboratory-specific one, and regulators weight it heavily for exactly that reason. A hundred papers from one group is not equivalent to a hundred papers from thirty groups, and the distinction is methodological rather than personal.

What the human evidence actually consists of

Here the picture is much thinner than the discussion around BPC-157 suggests, and it is worth enumerating precisely.

A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 544 articles and found a single human clinical study meeting inclusion criteria. [3]

A separate 2025 review searching six databases reached the same conclusion and described the human pharmacokinetic profile as critically undercharacterised. Human pharmacokinetics — what the compound does in a human body over time — has essentially not been established.

The published human safety data centres on a 2025 pilot study of intravenous BPC-157, which enrolled two participants. [4]

It reported tolerability without serious adverse events, and its authors were appropriately clear that a study of that size cannot establish safety.

Beyond that there are a small number of uncontrolled reports from a single for-profit clinic, including a chart review of knee pain in sixteen patients and a small study in interstitial cystitis. These share a lead author. None is randomised, none is controlled, and none addresses the claim most commonly made for BPC-157 — that it improves recovery and repair in otherwise healthy people.

There is no published, peer-reviewed randomised controlled trial demonstrating that BPC-157 is effective for any indication in humans. That statement is not a rhetorical flourish. It is the current state of the literature, and it has been confirmed by multiple independent reviews.

The trial that was never published

The most frequently cited piece of human evidence deserves its own section, because it is routinely described in a way that misleads.

In the early 2000s, the Croatian pharmaceutical company Pliva developed BPC-157 for inflammatory bowel disease under the designations PL-14736, PL-10 and PLD-116. The programme included a phase 1 safety study and a randomised, double-blind, placebo-controlled phase 2 study in ulcerative colitis. Those trials were completed. Neither was published in a peer-reviewed journal, and Pliva subsequently discontinued development.

Secondary sources describing BPC-157 as having "reached phase 2 trials in IBD with demonstrated efficacy" are citing this programme, generally via review articles written by the compound's originators, not via published trial results. The results are not in the public record.

What can be inferred is limited, and it cuts in an uncomfortable direction. A sponsor ran a properly designed randomised controlled trial, saw the outcome, and abandoned the compound. That is not proof the drug failed — programmes are dropped for commercial, portfolio and financing reasons all the time, and Pliva was acquired during this period. But it is the one occasion when rigorous human evidence was generated, and the compound did not go forward.

Where the evidence does point

None of this makes BPC-157 useless, and dismissing it outright would misrepresent the literature in the opposite direction.

The preclinical signal in gastrointestinal injury models is the strongest and most internally consistent part of the record, which is unsurprising given that the compound was identified in gastric juice. The proposed mechanisms are specific and testable rather than vague. And unlike many compounds circulating in this market, BPC-157 has a coherent origin story, a defined sequence, and a genuine research programme behind it.

There is also at least one registered phase 2 trial in acute hamstring strain, which is the kind of study that could actually settle something. If it completes and publishes, the picture changes.

The honest position is that BPC-157 is a plausible compound that has never been adequately tested in humans, thirty years after it was described. The reasons for that are structural — an unusual regulatory classification, no patent-protected commercial sponsor with an incentive to spend a decade and a substantial sum on registration trials — rather than evidence of a cover-up.

Regulatory position

The compound's legal status has moved repeatedly and is not settled.

BPC-157 was placed in Category 2 of the FDA's interim bulks list in late 2023, restricting it from compounding, and removed from that category in April 2026. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 to recommend its inclusion on the 503A list, against the written recommendation of FDA review staff. Formal listing requires notice-and-comment rulemaking, which remains incomplete. BPC-157 is not FDA approved for any indication.

Internationally the direction differs. In April 2026 the UK medicines regulator opened an investigation into peptide clinics making health claims about compounds they cannot lawfully sell as medicines, and BPC-157 was named first. [5]

What this means in practice

For a clinician, three things follow.

Any use is experimental, and the consent conversation should say so explicitly — not as a liability formality, but because a patient who believes they are receiving a validated treatment has not actually consented to what is happening. Telling someone the human evidence consists of a two-person safety pilot is more respectful of their autonomy than telling them it is well studied.

Product identity is a separate and serious problem. Independent testing of directly marketed research peptides finds high rates of quality failure, so even a clinician satisfied by the mechanistic case cannot assume the vial contains what the label claims.

And claims made in marketing materials carry regulatory exposure independent of clinical judgement. "Heals tendons" and "repairs the gut" are efficacy claims for an unapproved drug, and both the FDA and now the MHRA have signalled interest in them.

The underlying question — does BPC-157 accelerate tissue repair in humans — remains genuinely open. Thirty years of rodent data say it is worth finding out. They do not say we know.

For how to have this conversation with patients, see The peptide conversation: what your patients are already googling. For the current compounding position, see Is peptide therapy legal in your state?.